Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × INDUSTRY × Lambert-Eaton Myasthenic Syndrome × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 605 Breast Neoplasms 521 Neoplasms 405 Colorectal Neoplasms 263 Prostatic Neoplasms 239 Neoplasm Metastasis 234 Melanoma 215 Ovarian Neoplasms 197 Recurrence 191 Lung Neoplasms 176 Multiple Myeloma 169 Pancreatic Neoplasms 139 Lymphoma, Non-Hodgkin 139 Leukemia, Myeloid, Acute 129 Carcinoma, Hepatocellular 127 Stomach Neoplasms 126 Lymphoma 113 Glioblastoma 110 Carcinoma, Renal Cell 109 Head and Neck Neoplasms 101 Squamous Cell Carcinoma of Head and Neck 100 Small Cell Lung Carcinoma 91 Lymphoma, Follicular 91 Lymphoma, Large B-Cell, Diffuse 88 Leukemia, Lymphocytic, Chronic, B-Cell 88 Leukemia 86 Brain Neoplasms 83 Carcinoma 72 Uterine Cervical Neoplasms 67 Sarcoma 65

Interventions

Amifampridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01511978 2017-07-11

DAPPER

Jacobus Pharmaceutical

Phase 2 Completed

32 enrolled 16 charts

Lambert-Eaton Myasthenic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡